Stable Coronary Artery Disease (Management of)
ESC Clinical Practice Guidelines
Chronic Ischaemic Heart Disease (IHD)
These guidelines should be applied to patients with stable known or suspected coronary artery disease (SCAD).
The web addenda to the 2013 SCAD Guidelines contains additional material which should be used for further clarifications when reading the main document. The numbering of the chapters in this web document corresponds to the chapter numbering in the main document.
EMA and ESC statements on ivabradine
Current versions available to download
Gilles Montalescot (Chairperson) (France), Udo Sechtem (Chairperson) (Germany), Stephan Achenbach (Germany), Felicita Andreotti (Italy), Chris Arden (UK), Andrzej Budaj (Poland), Raffaele Bugiardini (Italy), Filippo Crea (Italy), Thomas Cuisset (France), Carlo Di Mario (UK), J. Rafael Ferreira (Portugal), Bernard J. Gersh (USA), Anselm K. Gitt (Germany), Jean-Sebastien Hulot (France), Nikolaus Marx (Germany), Lionel H. Opie (South Africa), Matthias Pfisterer (Switzerland), Eva Prescott (Denmark), Franck Ruschitzka (Switzerland), Manel Sabaté (Spain), Roxy Senior (UK), David Paul Taggart (UK), Ernst E. van der Wall (Netherlands), Christiaan J.M. Vrints (Belgium)
Declarations of Interest of the experts involved in the elaboration of the document.
Table of contents: Full Text (ESC Clinical Practice Guidelines)
- Definition & pathophysiology (see web addenda)
- Natural history and prognosis
- Diagnosis and assessemnt (see web addenda)
- Symptoms and signs (see web addenda), non-invasive cardiac investigations, invasive coronary angiography (see web addenda), stratification for risk of events (see web addenda), diagnostic aspects in the asymptomatic individual without known coronary artery disease (see web addenda), management aspects in the patient with known coronary artery disease, special diagnostic considerations:angina with 'normal' coronary arteries (see web addenda)
- Lifestyle and pharmacological management
- Risk factors and ischaemia management, event prevention, other drugs, strategy, treatment of particular forms of SCAD
- Percutaneous coronary invervention,coronary artery bypass surgery, revascularization vs. medical therapy, percutaneous coronary intervention vs. coronary artery bypass graft (see web addenda), scores and decisions (see web addenda)
- Special groups or considerations
- Women (see web addenda), patients with diabetes (see web addenda), patients with chronic kidney disease (see web addenda), elderly patients (see web addenda), the patient after revascularization (see web addenda), repeart revascularization of the patient with prior coronary artery bypass graft revascularization (see web addenda), chronic total occlusions (see web addenda), refractory angina (see web addenda), primary care (see web addenda), gaps in evidence (see web addenda)